All In Biotech

Free tool

FAERS Monitor: Qinlock

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213973 or its brand name (Qinlock, Ripretinib). Reports on generic versions are filed under their own applications.

Reports

5,243

Serious

2,276

43% of reports

Hospitalization

1,051

Death reported

497

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue688
  • alopecia594
  • death381
  • underdose374
  • extra dose administered357
  • nausea338
  • drug ineffective334
  • hospitalisation319
  • disease progression298
  • pain295
  • constipation292
  • diarrhoea279
  • inappropriate schedule of product administration278
  • product use in unapproved indication267
  • neoplasm progression265

Reports by year received

View as table
YearReports
2020303
2021727
2022833
2023951
2024842
20251,016
2026571

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,916 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
extra dose administeredSignal35735.732.211,910
neoplasm progressionSignal26530.827.47,567
underdoseSignal37420.718.76,964
alopeciaSignal59412.211.36,116
disease progressionSignal29810.19.12,450
hospitalisationSignal3198.37.52,065
inappropriate schedule of product administrationSignal2786.25.51,215
constipationSignal2925.44.81,045
product use in unapproved indicationSignal2674.33.8687
fatigueSignal6883.53.31,303
pain2951.91.7134
death3811.81.6133
diarrhoea2791.71.589
nausea3381.71.5104
drug ineffective3341.00.90

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.